The zinc finger antiviral protein (ZAP) is an interferon- and IRF3-induced host protein that inhibits replication of members of several virus families. Although the existence of two isoforms (ZAPS and ZAPL) has been appreciated for some time, new preliminary evidence demonstrates protein expression of at least four isoforms. This project will determine the antiviral spectrum of the four individual isoforms of ZAP: ZAPS, ZAPL and the newly identified ZAPM and ZAPXL against viruses known to be sensitive to ZAP's effect, including the alphaviruses Sindbis virus (SINV), chikungunya virus (CHIKV) and Venezuelan equine encephalitis virus (VEEV), human immunodeficiency virus type 1 (HIV-1), Ebola virus (EBOV) and hepatitis B virus (HBV). Moreover, the the antiviral activity of the individual isoforms of this important component of the host cell's innate immune response will be characterized for viruses not previously tested for ZAP sensitivity. The effects of the isoforms on translation (usin the SINV genome), miRNA-mediated translational arrest and interferon induction will be ascertained. The studies will determine if the isoforms have unique biological activities and whether these activities require cooperation between isoforms. Finally, the work will determine the contributions of ZAP ADP-ribosylation to ZAP function, and the role of the alphavirus nsP3 macrodomain in ADP-ribose removal and ZAP antagonism. Together the results obtained from these studies will have far reaching impact, affecting areas as diverse as translation control, innate immunity, numerous virus fields, macrodomain function and the role in protein function of ADP- ribosylation. The studies will clarify our understanding of ZAP function, in particular defining whether the different isoforms have unique biological activities. Knowledge gained can be leveraged for the development of safe and effective vaccines as well as novel antiviral approaches including macrodomain antagonists and ZAP mimics.

Public Health Relevance

The zinc finger antiviral protein (ZAP) is a host protein that inhibits replication of members of several virus families. This project will determine the ability f the four ZAP isoforms, ZAPS, ZAPM, ZAPL and ZAPXL, to inhibit the known ZAP-sensitive viruses, including the alphaviruses, HIV, Ebola virus and hepatitis B virus, as well as a panel of previously untested viruses. Whether the different isoforms function uniquely in ZAP's biological activities of translation inhibition, miRNA-mediated translational arrest and interferon induction, and the roles of ZAP ADP-ribosylation and alphavirus macrodomain- mediated ZAP antagonism will also be interrogated. The studies will impact diverse fields and lead to novel vaccine and therapy approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI114873-02
Application #
9110225
Study Section
Virology - B Study Section (VIRB)
Program Officer
Repik, Patricia M
Project Start
2015-07-15
Project End
2019-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Microbiology/Immun/Virology
Type
Graduate Schools
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Li, Melody M H; Lau, Zerlina; Cheung, Pamela et al. (2017) TRIM25 Enhances the Antiviral Action of Zinc-Finger Antiviral Protein (ZAP). PLoS Pathog 13:e1006145
Wang, Xinlu; Li, Melody M H; Zhao, Jing et al. (2016) Sindbis Virus Can Exploit a Host Antiviral Protein To Evade Immune Surveillance. J Virol 90:10247-10258
Li, Melody M H; MacDonald, Margaret R; Rice, Charles M (2015) To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes. Trends Cell Biol 25:320-9